A Hormone Therapy Reduced Symptoms Of Menopause In Phase 3 Trial - Revyuh

6/11/2022 12:00:00 AM2 years 10 months ago

A Phase 3 study found that Fezolinetant halved the frequency and severity of moderate-to-severe vasomotor symptoms (VMS), or hot flashes, caused by

A Phase 3 study found that Fezolinetant halved the frequency and severity of moderate-to-severe vasomotor symptoms (VMS), or hot flashes, caused by menopause. The SKYLIGHT 2 experiment was 52-week r… [+2107 chars]

full article...